Cargando…

Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States

BACKGROUND: Individuals with schizophrenia are a vulnerable and under-served population who are also at risk for severe morbidity and mortality following COVID-19 infection. Our research was designed to identify factors that put individuals with schizophrenia at increased risk of COVID-19 infection....

Descripción completa

Detalles Bibliográficos
Autores principales: Liberman, Joshua N., Pesa, Jacqueline, Petrillo, Mary Pat, Ruetsch, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161755/
https://www.ncbi.nlm.nih.gov/pubmed/35655167
http://dx.doi.org/10.1186/s12888-022-04026-7
_version_ 1784719550920523776
author Liberman, Joshua N.
Pesa, Jacqueline
Petrillo, Mary Pat
Ruetsch, Charles
author_facet Liberman, Joshua N.
Pesa, Jacqueline
Petrillo, Mary Pat
Ruetsch, Charles
author_sort Liberman, Joshua N.
collection PubMed
description BACKGROUND: Individuals with schizophrenia are a vulnerable and under-served population who are also at risk for severe morbidity and mortality following COVID-19 infection. Our research was designed to identify factors that put individuals with schizophrenia at increased risk of COVID-19 infection. METHODS: This study was a retrospective cohort analysis of medical and pharmacy claims among 493,796 individuals residing in the United States with schizophrenia or schizoaffective disorder, between January 1, 2019 and June 30, 2020. A confirmed diagnosis of COVID-19 infection by September 30, 2020 was regressed on demographics, social determinants, comorbidity, and pre-pandemic (December 2019 – February 2020) healthcare utilization characteristics. RESULTS: A total of 35,249 (7.1%) individuals were diagnosed with COVID-19. Elevated odds of COVID-19 infection were associated with age, increasing consistently from 40-49 years (OR: 1.16) to 80+ years (OR:5.92), male sex (OR: 1.08), Medicaid (OR: 2.17) or Medicare (OR: 1.23) insurance, African American race (OR: 1.42), Hispanic ethnicity (OR: 1.23), and higher Charlson Comorbidity Index. Select psychiatric comorbidities (depressive disorder, adjustment disorder, bipolar disorder, anxiety, and sleep-wake disorder) were associated with elevated odds of infection, while alcohol use disorder and PTSD were associated with lower odds. A pre-pandemic psychiatry (OR:0.56) or community mental health center (OR:0.55) visit were associated with lower odds as was antipsychotic treatment with long-acting injectable antipsychotic (OR: 0.72) and oral antipsychotic (OR: 0.62). CONCLUSIONS: Among individuals with schizophrenia, risk of COVID-19 infection was substantially higher among those with fewer economic resources, with greater medical and psychiatric comorbidity burden, and those who resided in African American or Hispanic communities. In contrast, individuals actively engaged in psychiatric treatment had substantially lower likelihood of infection. These results provide insights for healthcare providers that can translate into improved identification of at-risk individuals and interventions to reduce the risk and consequences of COVID-19 infection.
format Online
Article
Text
id pubmed-9161755
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91617552022-06-02 Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States Liberman, Joshua N. Pesa, Jacqueline Petrillo, Mary Pat Ruetsch, Charles BMC Psychiatry Research BACKGROUND: Individuals with schizophrenia are a vulnerable and under-served population who are also at risk for severe morbidity and mortality following COVID-19 infection. Our research was designed to identify factors that put individuals with schizophrenia at increased risk of COVID-19 infection. METHODS: This study was a retrospective cohort analysis of medical and pharmacy claims among 493,796 individuals residing in the United States with schizophrenia or schizoaffective disorder, between January 1, 2019 and June 30, 2020. A confirmed diagnosis of COVID-19 infection by September 30, 2020 was regressed on demographics, social determinants, comorbidity, and pre-pandemic (December 2019 – February 2020) healthcare utilization characteristics. RESULTS: A total of 35,249 (7.1%) individuals were diagnosed with COVID-19. Elevated odds of COVID-19 infection were associated with age, increasing consistently from 40-49 years (OR: 1.16) to 80+ years (OR:5.92), male sex (OR: 1.08), Medicaid (OR: 2.17) or Medicare (OR: 1.23) insurance, African American race (OR: 1.42), Hispanic ethnicity (OR: 1.23), and higher Charlson Comorbidity Index. Select psychiatric comorbidities (depressive disorder, adjustment disorder, bipolar disorder, anxiety, and sleep-wake disorder) were associated with elevated odds of infection, while alcohol use disorder and PTSD were associated with lower odds. A pre-pandemic psychiatry (OR:0.56) or community mental health center (OR:0.55) visit were associated with lower odds as was antipsychotic treatment with long-acting injectable antipsychotic (OR: 0.72) and oral antipsychotic (OR: 0.62). CONCLUSIONS: Among individuals with schizophrenia, risk of COVID-19 infection was substantially higher among those with fewer economic resources, with greater medical and psychiatric comorbidity burden, and those who resided in African American or Hispanic communities. In contrast, individuals actively engaged in psychiatric treatment had substantially lower likelihood of infection. These results provide insights for healthcare providers that can translate into improved identification of at-risk individuals and interventions to reduce the risk and consequences of COVID-19 infection. BioMed Central 2022-06-02 /pmc/articles/PMC9161755/ /pubmed/35655167 http://dx.doi.org/10.1186/s12888-022-04026-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liberman, Joshua N.
Pesa, Jacqueline
Petrillo, Mary Pat
Ruetsch, Charles
Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States
title Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States
title_full Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States
title_fullStr Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States
title_full_unstemmed Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States
title_short Factors associated with COVID-19 Infection among a national population of individuals with schizophrenia or schizoaffective disorder in the United States
title_sort factors associated with covid-19 infection among a national population of individuals with schizophrenia or schizoaffective disorder in the united states
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161755/
https://www.ncbi.nlm.nih.gov/pubmed/35655167
http://dx.doi.org/10.1186/s12888-022-04026-7
work_keys_str_mv AT libermanjoshuan factorsassociatedwithcovid19infectionamonganationalpopulationofindividualswithschizophreniaorschizoaffectivedisorderintheunitedstates
AT pesajacqueline factorsassociatedwithcovid19infectionamonganationalpopulationofindividualswithschizophreniaorschizoaffectivedisorderintheunitedstates
AT petrillomarypat factorsassociatedwithcovid19infectionamonganationalpopulationofindividualswithschizophreniaorschizoaffectivedisorderintheunitedstates
AT ruetschcharles factorsassociatedwithcovid19infectionamonganationalpopulationofindividualswithschizophreniaorschizoaffectivedisorderintheunitedstates